Anti SIRP-α antibodies and bi-specific macrophage enhancing antibodies

US10781256B2 · kind B2 · utility

Assignee

• The Board of Trustees of the Leland Stanford Junior University · US

Inventors

• Kipp Andrew Weiskopf · Sudbury, US
• Aaron Michael Ring · New Haven, US
• Jens-Peter Volkmer · Menlo Park, US
• Irving L. Weissman · Palo Alto, US
• Nan Guo Ring · New Haven, US

Key dates

• Filing date: Jul 9, 2018
• Grant date: Sep 22, 2020
• Expiry date: Mar 28, 2039

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2333/70503
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Anti-SIRPα antibodies, including multi-specific anti-SIRPα antibodies, are provided, as are related compositions and methods. The antibodies of the disclosure bind to SIRPα and can block the interaction of CD47 on one cell with SIRPα on a phagocytic cell. Antibodies that are bispecific for SIRPα and a second antigen are termed Bi-specific Macrophage Enhancing (BiME) antibodies and have emergent properties. The subject anti-SIRPα antibodies find use in various therapeutic methods. Embodiments of the disclosure include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the anti-SIRPα antibodies; and cell lines that produce the antibodies. Also provided are amino acid sequences of exemplary anti-SIRPα antibodies.